QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=6C6BDE07D48282C27BCE64B0428EEB1D;jsessionid=3504E2527763B80DB278C6A5C76A32B7;jsessionid=55354BCEEF35E809269CA345E89F4BD6;jsessionid=0235EEF1A3CE7E8DC2504495E59F41B7;jsessionid=D2C818AC51D83DE0C2272A0CCD345CD0;jsessionid=B30D7BFFE02DEC242CDF14E0EC1B6DE3 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=6C6BDE07D48282C27BCE64B0428EEB1D;jsessionid=3504E2527763B80DB278C6A5C76A32B7;jsessionid=55354BCEEF35E809269CA345E89F4BD6;jsessionid=0235EEF1A3CE7E8DC2504495E59F41B7;jsessionid=D2C818AC51D83DE0C2272A0CCD345CD0;jsessionid=B30D7BFFE02DEC242CDF14E0EC1B6DE3